Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CXCL16 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CXCL16 ECD-Fc Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View CXCL16 Products |
| Gene Delivery | CXCR6 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction to perform chemotaxis and binding assays. |
View CXCR6 Products |
| Benchmark Ab | Anti-CXCL16 Recombinant Antibody Recombinant positive control derived from clinical benchmark sequences. |
View CXCL16 Products |
| Validator | CXCL16 siRNA Set Target-specific knockdown pool for specificity and target validation. |
View CXCL16 Products |
| Related Target A | CXCR6 The cognate GPCR receptor for CXCL16, driving immune cell trafficking and tumor microenvironment modulation. |
View CXCR6 Products |
| Related Target B | ADAM10 Primary metalloproteinase responsible for shedding membrane-bound CXCL16 into its soluble chemotactic form. |
View ADAM10 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Differentiating membrane-bound vs. soluble CXCL16 binding | Truncated ECD-Fc proteins and full-length Lentivirus vectors enable distinct conformation modeling. |
| Receptor binding and chemotaxis assay reproducibility | High-titer CXCR6 Lentivirus ensures stable receptor expression on target cell lines for flow cytometry and migration assays. |
| Lack of clinical benchmark controls | Sequence-verified recombinant benchmark antibodies included in the catalog. |
| Off-target validation in complex matrices | Sequence-verified siRNA sets provide robust loss-of-function validation in primary cells. |
Live CXCL16 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the CXCL16/CXCR6 axis is gaining significant momentum in both oncology and inflammatory disease indications. CXCL16 is unique as a transmembrane chemokine that can be cleaved by disintegrin and metalloproteinases (ADAM10 and ADAM17) to release a soluble chemotactic factor. This dual role makes it a complex but highly rewarding target.
The race for CXCL16 therapeutics is intensifying, with major players shifting focus from traditional systemic chemokine blockade to localized tumor microenvironment modulation and CAR-T cell trafficking enhancement. As first-generation therapies reach the clinic, the next wave of R&D is targeting the selective inhibition of soluble CXCL16 shedding or engineering CXCR6-expressing cell therapies to home in on CXCL16-expressing solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Academic Institutes, Biotech Consortia | NASH, Liver Fibrosis, Glioblastoma | High-purity ECD-Fc proteins for affinity kinetics (SPR/BLI) and epitope mapping. |
| CAR-T (CXCR6-modified) | Clinical-stage Cell Therapy Developers | Solid Tumors (Pancreatic, Ovarian) | CXCL16 recombinant proteins to validate CAR binding; CXCR6 Lentivirus for positive control lines. |
| Small Molecule Inhibitors | Pharmaceutical Lead-Gen Teams | Inflammatory Bowel Disease (IBD) | High-throughput cell migration assays utilizing stable CXCR6-expressing cell lines. |